menu
    • menu

    Company profile for Genmab

    NEW Drugs in Dev: 30
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and pre-clinical product pipeline and three proprietary next generation antibody technologies. Genmab has two partnered products on the market, DARZALEX® (daratumumab) and Arz...
    Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and pre-clinical product pipeline and three proprietary next generation antibody technologies. Genmab has two partnered products on the market, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and is developing a clinical pipeline of antibody therapeutics for the treatment of cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GenmabDenmark Flag
    Country
    Country
    Denmark
    Address
    Address
    Kalvebod Brygge 43 1560 Copenhagen V
    Telephone
    Telephone
    +45 7020 2728
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.genmab.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/genmab
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Genmab

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Genmab Sees Capital Boost From Employee Warrant Exercise
    Genmab Sees Capital Boost From Employee Warrant Exercise

    12 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/12/3293286/0/en/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise.html

    GLOBENEWSWIRE
    12 May 2026
    Share Share
    Major Shareholder Announcement
    Major Shareholder Announcement

    08 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/08/3291306/0/en/major-shareholder-announcement.html

    GLOBENEWSWIRE
    08 May 2026
    Share Share
    Genmab Announces Financial Results For The First Quarter Of 2026
    Genmab Announces Financial Results For The First Quarter Of 2026

    07 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/07/3290274/0/en/genmab-announces-financial-results-for-the-first-quarter-of-2026.html

    GLOBENEWSWIRE
    07 May 2026
    Share Share
    Genmab A/S Share Capital Reduction
    Genmab A/S Share Capital Reduction

    17 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/17/3276312/0/en/Genmab-A-S-Share-Capital-Reduction.html

    GLOBENEWSWIRE
    17 Apr 2026
    Share Share
    Major Shareholder Announcement
    Major Shareholder Announcement

    14 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/14/3273631/0/en/Major-Shareholder-Announcement.html

    GLOBENEWSWIRE
    14 Apr 2026
    Share Share
    Genmab Announces DARZALEX Net Sales for Q1 2026
    Genmab Announces DARZALEX Net Sales for Q1 2026

    14 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/14/3273148/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-First-Quarter-of-2026.html

    GLOBENEWSWIRE
    14 Apr 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Genmab and get a quotation

    Genmab is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find HUMAN MONOCLONAL ANTIBODY TO CD4 (ZANOLIMUNAB) bulk offered by Genmab

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search